FGF2 and atherosclerosis: Inhibition of the bFGF-induced increase in KCNN4 mRNA, protein, and channel activity by treatment with Apo indicates a critical role for NOX in KCNN4 regulation and provides a novel pathway for NOX to contribute to the progression of atherosclerosis.